Literature DB >> 19914435

Effective desensitization to imiglucerase in a patient with type I Gaucher disease.

Diego G Peroni1, Lydia Pescollderungg, Giorgio L Piacentini, Walburga Cassar, Attilio L Boner.   

Abstract

We describe a child who had anaphylactic hypersensitivity to imiglucerase therapy for Gaucher disease. Treatment was stopped and symptoms returned. After immune desensitization to imiglucerase using a rush protocol, the patient was able to resume treatment and has not had further hypersensitivity complications to date.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19914435     DOI： 10.1016/j.jpeds.2009.05.033

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  6 in total

1.  Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment.

Authors:  Filippo Vairo; Cristina Netto; Alicia Dorneles; Suzana Mittelstadt; Matheus Wilke; Divair Doneda; Kristiane Michelin; Camila Blos Ribeiro; Amanda Quevedo; Tatiane Vieira; Tatiele Nalin; Sônia Lueska; Ida Vanessa D Schwartz
Journal:  JIMD Rep       Date:  2013-02-21

2.  Successful Desensitisation in a Patient with CRIM-Positive Infantile-Onset Pompe Disease.

Authors:  J Baruteau; A Broomfield; V Crook; N Finnegan; K Harvey; D Burke; M Burch; G Shepherd; A Vellodi
Journal:  JIMD Rep       Date:  2013-09-04

Review 3.  Management of multiple drug allergies in children.

Authors:  Anahita Falakshahi Dioun
Journal:  Curr Allergy Asthma Rep       Date:  2012-02       Impact factor: 4.806

4.  An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions.

Authors:  Areeg H El-Gharbawy; Joanne Mackey; Stephanie DeArmey; Greg Westby; Sherry G Grinnell; Peggy Malovrh; Robert Conway; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2011-07-13       Impact factor: 4.797

5.  Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.

Authors:  Gaetano Giuffrida; Rita Lombardo; Ernesto Di Francesco; Laura Parrinello; Francesco Di Raimondo; Agata Fiumara
Journal:  J Med Case Rep       Date:  2016-11-08

Review 6.  Inherited and acquired determinants of serum tryptase levels in humans.

Authors:  Jonathan J Lyons
Journal:  Ann Allergy Asthma Immunol       Date:  2021-06-24       Impact factor: 6.248
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.